Anika Therapeutics
ANIK
117 hedge funds and large institutions have $340M invested in Anika Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 12 closing their positions.
3,942% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $26K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
0.57% less ownership
Funds ownership: 89.32% → 88.76% (-0.57%)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
3% less funds holding
Funds holding: 120 → 117 (-3)
9% less capital invested
Capital invested by funds: $376M → $340M (-$35.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$5.57M |
| 2 |
Millennium Management
New York
|
+$3.28M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.26M |
| 4 |
Renaissance Technologies
New York
|
+$1.55M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$8.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.34M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.85M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.47M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.04M |
ANIK Hedge Fund Activity: Q2 2023 in Review
117 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2023, worth a combined $340M — down 9.5% from $376M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ANIK and 11 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 45 added.
The largest buyer was Trigran Investments, adding an estimated $5.57M. The largest seller was Janus Henderson Group, cutting an estimated $8.27M.
- 117 institutional investors held Anika Therapeutics (ANIK) as of Q2 2023, down from 120 in Q1 2023.
- Funds reported $340M of Anika Therapeutics stock for Q2 2023, down 9.5% quarter-over-quarter.
- 11 funds opened new Anika Therapeutics positions in Q2 2023 and 12 closed out, a net change of -1 holder.
- The largest Anika Therapeutics buyer in Q2 2023 was Trigran Investments, an estimated $5.57M added.
- The largest Anika Therapeutics seller in Q2 2023 was Janus Henderson Group, an estimated $8.27M sold.
Based on aggregated 13F filings for Q2 2023.